<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036811</url>
  </required_header>
  <id_info>
    <org_study_id>NRIPH_2020_11</org_study_id>
    <nct_id>NCT05036811</nct_id>
  </id_info>
  <brief_title>HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)</brief_title>
  <acronym>MAIVIH</acronym>
  <official_title>HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Follow-up registry of patients living with HIV who also have various inflammatory and&#xD;
      autoimmune pathologies that may require immunosuppressive treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients living with HIV who have an inflammatory or autoimmune disease</measure>
    <time_frame>At the end of the study an average of 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients on immunosuppressive treatment,</measure>
    <time_frame>At the end of the study an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of infectious complications</measure>
    <time_frame>At the end of the study an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients on remission</measure>
    <time_frame>At the end of the study an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of CD4 and HIV viral load</measure>
    <time_frame>At the end of the study an average of 18 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hiv</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>data collection</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HIV and an inflammatory or autoimmune disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient living with HIV&#xD;
&#xD;
          -  Carrier of one or more of the following diseases:&#xD;
&#xD;
        Sarcoidosis Multiple sclerosis Myasthenia gravis Crohn's disease Hemorrhagic rectocolitis&#xD;
        Autoimmune hepatitis Arthropathic psoriasis Still's disease, other rheumatoid arthritides,&#xD;
        juvenile polyarthritides, Rheumatoid arthritis Vasculitides: periarteritis nodosa and&#xD;
        related conditions, other necrotizing vasculopathies (periarteritis nodosa, juvenile&#xD;
        periarteritis, Churg-Strauss disease, polyangiitis, Kawasaki disease, Horton's disease,&#xD;
        Wegener's disease, thrombotic microangiopathy, Takayashu syndrome, Good-Pasture's syndrome,&#xD;
        thrombocytopenic purpura) Lupus Polymyositis or dermatopolymyositis Connectivitis (Behcet's&#xD;
        disease, Gougerot-Sj√∂ogren syndrome) Inflammatory spondyloarthropathies (APS,&#xD;
        spondyloarthritis, other spondyloarthropathies)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition of the person&#xD;
&#xD;
          -  Minor patients&#xD;
&#xD;
          -  Patients under judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nathalie VIGET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie VIGET, MD</last_name>
    <phone>0320694848</phone>
    <email>nviget@ch-tourcoing.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solange TREHOUX, PhD</last_name>
    <phone>0320694280</phone>
    <email>strehoux@ch-tourcoing.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

